These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37469693)

  • 1. Erratum: Nitrous oxide: a unique official French addictovigilance national survey.
    Frontiers Production Office
    Front Public Health; 2023; 11():1235720. PubMed ID: 37469693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrous oxide: a unique official French addictovigilance national survey.
    Guerlais M; Aquizerate A; Lionnet A; Daveluy A; Duval M; Gérardin M; Istvan M; Laforgue EJ; Victorri-Vigneau C;
    Front Public Health; 2023; 11():1167746. PubMed ID: 37206871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yes, nitrous oxide addiction undeniably exists!
    Victorri-Vigneau C; Grall Bronnec M
    Addiction; 2024 Apr; 119(4):625-626. PubMed ID: 38196069
    [No Abstract]   [Full Text] [Related]  

  • 4. Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
    Lapeyre-Mestre M; Boucher A; Daveluy A; Gibaja V; Jouanjus E; Mallaret M; Peyrière H; Micallef J;
    Therapie; 2020; 75(4):343-354. PubMed ID: 32660776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex/gender differences in spontaneous reports to a French Addictovigilance centre.
    Peyriére H; Dampierre A; Vallo R; Lestienne M; Eiden C; Donnadieu H
    Arch Womens Ment Health; 2024 Jul; ():. PubMed ID: 38980402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?
    Gentile G; Jego M; Spadari M; Griffiths K; Jouanjus E; Micallef J
    Fundam Clin Pharmacol; 2018 Dec; 32(6):643-651. PubMed ID: 30003596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal identification in addictovigilance: the functioning of the French system.
    Jouanjus E; Gibaja V; Kahn JP; Haramburu F; Daveluy A
    Therapie; 2015; 70(2):113-31. PubMed ID: 25858567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on zolpidem abuse and dependence.
    Victorri-Vigneau C; Gérardin M; Rousselet M; Guerlais M; Grall-Bronnec M; Jolliet P
    J Addict Dis; 2014; 33(1):15-23. PubMed ID: 24467433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addictovigilance in women, the hidden part of the iceberg?
    Lapeyre-Mestre M
    Therapie; 2023; 78(2):157-164. PubMed ID: 36280399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrous oxide: What do we know about its use disorder potential? Results of the French Monitoring Centre for Addiction network survey and literature review.
    Fidalgo M; Prud'homme T; Allio A; Bronnec M; Bulteau S; Jolliet P; Victorri-Vigneau C
    Subst Abus; 2019; 40(1):33-42. PubMed ID: 30913001
    [No Abstract]   [Full Text] [Related]  

  • 11. [Twenty-five years of the French Addictovigilance Network (FAN)].
    Micallef J; Mallaret M
    Therapie; 2016 Sep; 71(4):375-8. PubMed ID: 27296806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)].
    Baumevieille M; Perri-Plandé J; Miremont-Salamé G; Daveluy A; Haramburu F
    Therapie; 2019 Jun; 74(3):375-382. PubMed ID: 30193805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health].
    Micallef J; Jouanjus É; Mallaret M; Lapeyre Mestre M
    Therapie; 2019 Dec; 74(6):579-590. PubMed ID: 31694770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemsex practice in France: An update in Addictovigilance data.
    Batisse A; Eiden C; Deheul S; Monzon E; Djezzar S; Peyrière H
    Fundam Clin Pharmacol; 2022 Apr; 36(2):397-404. PubMed ID: 34494320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of abuse/dependence cases by the French addictovigilance network (FAN): A pilot study of the addictovigilance center and the psychotherapeutic center of Nancy (France)].
    Barberot P; Gibaja V; Benkhedda C; Dobre D; Tournebize J; Kahn JP
    Therapie; 2019 Jun; 74(3):389-397. PubMed ID: 30392700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution.
    Dupui M; Micallef J; Lapeyre-Mestre M
    Therapie; 2019 Apr; 74(2):307-314. PubMed ID: 30798951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum: COVID-19: ramifications of the pandemic on mental health and substance abuse.
    Frontiers Production Office
    Front Public Health; 2024; 12():1477635. PubMed ID: 39351037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels.
    Largeau B; Karam A; Potey C; Caous AS; Tard C; Carton L; Kuchcinski G; Gautier S; Deheul S; Bordet R
    Eur J Neurol; 2022 Aug; 29(8):2173-2180. PubMed ID: 35460312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data.
    Roussin A; Soeiro T; Fouque C; Jouanjus E; Frauger E; Fouilhé N; Mallaret M; Micallef J; Lapeyre-Mestre M;
    Br J Clin Pharmacol; 2022 Aug; 88(8):3789-3802. PubMed ID: 35318713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warning on increased serious health complications related to non-medical use of nitrous oxide.
    ; Micallef J; Mallaret M; Lapeyre-Mestre M; Daveluy A; Victorri-Vigneau C; Peyrière H; Debruyne D; Deheul S; Bordet R; Chevallier C; Perault-Pochat MC; Le Boisselier R; Libert F; Chaouachi L; Gillet P
    Therapie; 2021; 76(5):478-479. PubMed ID: 32063400
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.